T1	eligibility 386 460	Women with axillary node-positive or high-risk node-negative breast cancer
T2	outcome-Measure 790 820	recurrence-free survival (RFS)
T3	intervention 0 66	Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin
T4	outcome 871 881	RFS events
T5	iv-bin-abs 944 946	96
T6	cv-bin-abs 959 962	118
T7	outcome 965 968	RFS
T8	outcome 892 930	local or distant recurrences or deaths
T11	outcome 1078 1088	5-year RFS
T12	iv-bin-percent 1090 1095	86.6%
T13	cv-bin-percent 1109 1114	84.1%
T14	iv-bin-abs 1127 1136	Fifty-six
T15	outcome 1165 1169	died
T16	cv-bin-abs 1205 1207	75
T19	outcome 1323 1354	breast cancer-specific survival
T9	control 749 752	CEF
T10	intervention-participants 635 638	753
T17	control-participants 758 761	747
T18	outcome 1402 1405	RFS
T20	outcome 1570 1578	toxicity
